Floatz Rating
BB71/100
Confidence
Indicative
Sponsor
Second Affiliated Hospital, School of Medicine, Zhejiang University
Modality
monoclonal_antibody
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
70High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07505095CT.gov Efficacy of Lecanemab at Different Therapeutic Doses for Alzheimer's Disease (AD) in Real-World Practice | — | Not Yet Recruiting | — | — | — |
NCT07604896CT.gov Evaluating the Efficacy and Safety of Lecanemab in Alzheimer's Disease Through Multi-omics Approachs | — | Recruiting | — | — | — |
NCT07212062CT.gov The Purpose of This Study is to Evaluate the Safety and Tolerability of X/T+X-EC in Participants With Alzheimer's Disease Who Are Currently Treated With Lecanemab. | — | Not Yet Recruiting | — | — | — |
NCT07152418CT.gov Therapeutic Efficacy of Monoclonal Antibody Drugs for Alzheimer's Disease Based on PET Research | — | Not Yet Recruiting | — | — | — |
NCT06871839CT.gov The Clinical Study of Synaptic Plasticity-based Lencanumab for the Treatment of Early Alzheimer's Disease | — | Recruiting | — | — | — |
NCT05999084CT.gov Georgia Memory Net Anti-Amyloid Monoclonal Antibody Registry | — | Recruiting | — | — | — |
NCT06602258CT.gov A Study of E2814 With Concurrent Lecanemab Treatment in Participants With Early Alzheimer's Disease | — | Active Not Recruiting | — | — | — |
NCT06741553CT.gov Prospective Cohort Study of Patients With Early Alzheimer's Disease Treated With Lecanemab | — | Recruiting | — | — | — |
NCT07034222CT.gov 12-Month Real-World Safety & Efficacy of Lecanemab in Early Alzheimer's Disease | — | Active Not Recruiting | — | — | — |
NCT05269394CT.gov Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation (DIAN-TU) | — | Active Not Recruiting | — | — | — |
Show 5 more trialsShow fewer
NCT03887455CT.gov A Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer's Disease | — | Active Not Recruiting | — | — | — |
NCT02094729CT.gov A Randomized, Double-blind, Placebo-controlled Study to Assess Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Pharmacodynamic Response of Repeated Intravenous Infusions of BAN2401 in Subjects With Mild Cognitive Impairment Due to Alzheimer's Disease and Mild Alzheimer's Disease | — | Completed | — | — | — |
NCT01767311CT.gov A Study to Evaluate Safety, Tolerability, and Efficacy of Lecanemab in Subjects With Early Alzheimer's Disease | — | Completed | — | — | — |
NCT01760005CT.gov Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation. Master Protocol DIAN-TU-001 | — | Active Not Recruiting | — | — | — |
NCT01230853CT.gov A Randomized, Double-blind, Placebo-controlled, Combined Single Ascending Dose and Multiple Ascending Dose Study | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Alzheimer Disease
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Lecanemab (this asset) | Second Affiliated Hospital, School of Medicine, Zhejiang University | Approved | BB · 71 |
| 4-((1E)-2-(6-(2-)2-(2-FLUOROETHOXY)ETHOXY)ETHOXY)PYRIDIN-3-YL)ETHENYL)-N-METHYLBENZENAMINE | Akiva Mintz | P4 | BBB |
| Memantine | Carnot Laboratories | P4 | BBB |
| Escitalopram | NYU Langone Health | P4 | BBB |
| Flortaucipir | Eli Radiopharma | P4 | BBB |
| Rivastigmine | Anhui Provincial Hospital | P4 | BBB |
| Florbetaben | National Institute of Mental Health (NIMH) | P4 | BBB |
| 6H-BENZOFURO(3A,3,2-EF)(2)BENZAZEPIN-6-OL, 4A,5,9,10,11,12-HEXAHYDRO-3-METHOXY-11-METHYL-, (4AS,6R,8AS) | Anhui Provincial Hospital | P4 | BBB |
| Sertraline | AstraZeneca | P4 | BBB |
+42 more in the Alzheimer Disease cohort
Other indications for Lecanemab
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Familial Alzheimer Disease | — | P3 | BB · 66 |
| Dementia | — | P3 | B · 62 |
| Alzheimer Disease Type 1 | — | Early P1 | C · 39 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Lecanemab in Alzheimer Disease. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 11, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/lecanemab-alzheimer-disease
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →